Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P240023/S004

WRAPSODY Cell-Impermeable Endoprosthesis

Merit Medical Systems, Inc. · Decision date Dec 11, 2025

FDA DECISIONP240023/S004

What did the FDA approve?

FDA records P240023/S004 as a supplement to PMA P240023, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Dec 11, 2025.

FDA approval order statement

approval of the revised protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P240023
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Cardiovascular
Decision date
Dec 11, 2025
FDA change category
Postapproval Study Protocol

FDA source record

Regulatory record facts

Identifier
P240023/S004
Regulatory pathway
PMA supplement
Product code
PFV
Decision code
APPR
Decision date
Dec 11, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: System, endovascular graft, arteriovenous (AV) dialysis access circuit stenosis treatment.

Product code
PFV
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P240023/S004 received

    Application receipt date recorded by FDA.

  2. P240023/S004 · FDA decision

    Normal 180 Day Track No User Fee

  3. P240023/S005 · Related supplement

    WRAPSODY Cell-Impermeable Endoprosthesis

Timeline entries are records held by MedtechLedger for P240023. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240023

Product / regulatory recordCompanyPathwayDecision dateSource
Merit Medical Systems, Inc.PMA supplementJun 11, 2026FDA

Explore the linked device profile

Other records with product code PFV

Product / regulatory recordCompanyPathwayDecision dateSource
Bard Peripheral Vascular, Inc.PMA supplementJun 22, 2026FDA
Bard Peripheral Vascular, Inc.PMA supplementJun 10, 2026FDA
C.R. Bard, Inc.PMA supplementJun 10, 2026FDA
W. L. Gore & Associates, Inc.PMA supplementMay 26, 2026FDA
C.R. Bard, Inc.PMA supplementDec 16, 2025FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Merit Medical Systems, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1600 W. Merit Pkwy., South Jordan, UT, 84095

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records